JP2010535814A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535814A5
JP2010535814A5 JP2010520325A JP2010520325A JP2010535814A5 JP 2010535814 A5 JP2010535814 A5 JP 2010535814A5 JP 2010520325 A JP2010520325 A JP 2010520325A JP 2010520325 A JP2010520325 A JP 2010520325A JP 2010535814 A5 JP2010535814 A5 JP 2010535814A5
Authority
JP
Japan
Prior art keywords
motomeko
opiate
active ingredient
side effects
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010520325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535814A (ja
JP5581211B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/072632 external-priority patent/WO2009023567A1/en
Publication of JP2010535814A publication Critical patent/JP2010535814A/ja
Publication of JP2010535814A5 publication Critical patent/JP2010535814A5/ja
Application granted granted Critical
Publication of JP5581211B2 publication Critical patent/JP5581211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010520325A 2007-08-09 2008-08-08 第四級オピオイドカルボキサミド Active JP5581211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95496007P 2007-08-09 2007-08-09
US60/954,960 2007-08-09
PCT/US2008/072632 WO2009023567A1 (en) 2007-08-09 2008-08-08 Quaternary opioid carboxamides

Publications (3)

Publication Number Publication Date
JP2010535814A JP2010535814A (ja) 2010-11-25
JP2010535814A5 true JP2010535814A5 (enExample) 2011-09-22
JP5581211B2 JP5581211B2 (ja) 2014-08-27

Family

ID=39941437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520325A Active JP5581211B2 (ja) 2007-08-09 2008-08-08 第四級オピオイドカルボキサミド

Country Status (14)

Country Link
US (4) US8263807B2 (enExample)
EP (1) EP2190819B1 (enExample)
JP (1) JP5581211B2 (enExample)
KR (1) KR101519682B1 (enExample)
CN (1) CN101827819B (enExample)
AU (1) AU2008286979B2 (enExample)
BR (1) BRPI0815020A2 (enExample)
CA (1) CA2694497C (enExample)
EA (1) EA020658B1 (enExample)
ES (1) ES2586245T3 (enExample)
IL (1) IL203459A (enExample)
MX (1) MX2010001371A (enExample)
NO (1) NO341089B1 (enExample)
WO (1) WO2009023567A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008331235C1 (en) * 2007-11-30 2013-01-17 Purdue Pharma L.P. Benzomorphan Compounds
EP2408303A4 (en) * 2009-03-19 2012-07-25 Alkermes Inc MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
PT2506712T (pt) * 2009-12-04 2019-05-31 Alkermes Pharma Ireland Ltd Derivados de morfinano para o tratamento da overdose por fármaco
ES2582306T3 (es) * 2010-03-22 2016-09-12 Rensselaer Polytechnic Institute Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides
JP5728084B2 (ja) * 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
EP2407469A1 (en) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
AU2012217903A1 (en) * 2011-02-14 2013-08-15 Alkermes, Inc. Peripherially acting mu opioid antagonists
AU2012247127B2 (en) * 2011-03-03 2016-01-28 Cadila Healthcare Limited Novel salts of DPP-IV inhibitor
US9029543B2 (en) * 2011-04-05 2015-05-12 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
ES2638329T3 (es) * 2011-06-29 2017-10-19 Alkermes, Inc. Compuestos opioides de acción periférica
WO2013084060A1 (en) * 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3153171B1 (en) 2011-12-15 2018-09-19 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
WO2016138103A1 (en) * 2015-02-25 2016-09-01 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN115521317B (zh) * 2021-02-02 2025-07-25 山东新时代药业有限公司 一种制备纳呋拉啡中间体的方法
WO2025104754A1 (en) * 2023-11-17 2025-05-22 Msn Laboratories Private Limited, R&D Center A process for the preparation of samidorphan and its intermediates
CN118598813B (zh) * 2024-08-08 2024-10-29 山东齐都药业有限公司 L-苹果酸萨米多芬及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB874217A (en) * 1958-10-30 1961-08-02 Albert Boehringer Normorphine derivatives
DE2254298A1 (de) * 1972-11-06 1974-05-16 Boehringer Sohn Ingelheim Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
CA1315689C (en) * 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
ES2121553B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion.
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
CA2380524A1 (en) * 1999-08-25 2001-03-01 Barrett R. Cooper Compositions and methods for treating opiate intolerance
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
ATE292625T1 (de) * 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
KR20050074462A (ko) * 2002-09-25 2005-07-18 유로-셀티큐 에스.에이. Ｎ―치환 하이드로모르폰 및 그 용도
US7285665B2 (en) * 2002-11-08 2007-10-23 Mallinckrodt Inc. Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
RU2480455C2 (ru) 2004-11-05 2013-04-27 Ренссилэйер Политекник Инститьют 4-гидроксибензоморфаны
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents

Similar Documents

Publication Publication Date Title
JP2010535814A5 (enExample)
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
MX2011012122A (es) Derivados de tiofeno.
JP2011522896A5 (enExample)
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
JP2007527914A5 (enExample)
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2009063222A3 (en) Solid compositions
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
JP2010222367A5 (enExample)
JP2009537554A5 (enExample)
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2008006795A3 (en) Indole compounds
JP2009522376A5 (enExample)
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
JP2008266291A5 (enExample)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2008144320A3 (en) Opioid and methods of making and using the same
WO2010142400A3 (de) Zusammensetzungen auf basis von chitosan-oligosacchariden